Vyndamax
My Prescription
Payment
Select pharmacy
$23,895.98
Print or send this coupon to your phone
CVSPowered byAbout Vyndamax
Drug Details
Tafamidis, marketed under the brand name Vyndaqel, is an oral medication prescribed for transthyretin-mediated amyloidosis cardiomyopathy (ATTR-CM), a rare heart condition. Its primary function is to prevent the progression of heart failure and reduce the need for hospitalization. Tafamidis acts by stabilizing a protein called transthyretin, which helps slow down the formation and accumulation of amyloid fibrils in the heart. This stabilization supports the heart's ability to pump blood more effectively. Please consult your healthcare provider to ensure this medication is suitable for your condition and to discuss any potential risks or benefits.
Price history for Vyndamax
30 Capsules, 61MG
Average retail price for Vyndamax
Average SaveHealth price for Vyndamax
Our price history data is based on aggregated prescription data collected from participating pharmacies in America. Our prescription data updates daily to reflect the latest price changes. If you notice a missing data point, it means there wasn't sufficient data available to generate a monetary value for that date.
*Retail prices are based on pharmacy claims data, and may not be accurate when we don't have enough claims.
Vyndamax dosage forms
| Dosage | Quantity | Price from | Per unit |
|---|---|---|---|
| 61MG | 30 Capsules | $23,895.98 | $796.53 |
| 61MG | 1 Capsule | $818.48 | $818.48 |
Vyndamax FAQs
Vyndamax is used for the treatment of transthyretin-mediated amyloidosis (ATTR-CM) in adults. This condition is a rare and progressive disease that affects the heart and is caused by the buildup of abnormal protein deposits.
The life expectancy of patients taking Vyndamax (tafamidis) can vary significantly depending on several factors, including the stage of the disease, the patient's overall health, and how well they respond to the treatment. Vyndamax is used to treat transthyretin amyloid cardiomyopathy, a condition that can affect life expectancy. Clinical studies have shown that Vyndamax can improve survival rates and quality of life in patients with this condition, but specific life expectancy should be discussed with a healthcare provider who can consider individual circumstances.
A drug similar to Vyndamax (tafamidis) is Vyndaqel, which also contains tafamidis as the active ingredient. Both are used to treat transthyretin amyloid cardiomyopathy, a condition that affects the heart.
Tafamidis is priced high due to several factors, including the costs associated with its research and development, the complexity of manufacturing, and the relatively small patient population it serves. Additionally, the drug's effectiveness in treating a rare and serious condition can contribute to its premium pricing. Pharmaceutical companies often set prices to recoup their investment and fund future research.
Vyndamax (tafamidis) may cause several side effects. Common side effects include urinary tract infections, stomach pain, and diarrhea. Less common side effects can include upper respiratory tract infections, headache, and back pain. It is important for patients to report any unusual or severe symptoms to their healthcare provider.